CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes

Yaqin Xia; Jurui Ge; Zhenchang Sun; Feifei Nan; Wenjuan Wan; Duo Xu; Mingzhi Zhang; Xiaorui Fu

doi:10.1016/j.leukres.2022.106840

CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes

Leuk Res. 2022 Jun:117:106840. doi: 10.1016/j.leukres.2022.106840. Epub 2022 Apr 12.

Authors

Yaqin Xia¹, Jurui Ge², Zhenchang Sun³, Feifei Nan⁴, Wenjuan Wan⁵, Duo Xu⁶, Mingzhi Zhang⁷, Xiaorui Fu⁸

Affiliations

¹ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. Electronic address: xiayaqin1029@foxmail.com.
² Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. Electronic address: 3030456868@qq.com.
³ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. Electronic address: suny006@163.com.
⁴ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. Electronic address: nanfeifei2008@126.com.
⁵ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. Electronic address: 869886116@qq.com.
⁶ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. Electronic address: 847457403@qq.com.
⁷ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. Electronic address: mingzhi_zhang1@163.com.
⁸ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. Electronic address: zymfxr_2006@126.com.

PMID: 35468520
DOI: 10.1016/j.leukres.2022.106840

Abstract

Background: CD5 expression in different B-cell lymphomas has different clinicopathological and prognosis and the value of CD5 expression in marginal zone lymphoma is undefined.

Methods: Clinicopathological features, survival outcomes of marginal zone lymphoma were retrospectively analyzed in 204 patients. We classified patients into (i) CD5-positive marginal zone lymphoma (ii) CD5-negative marginal zone Lymphoma, Fisher's exact test was used to compare the CD5-positive and CD5-negative marginal zone lymphoma. Progression-free survival (PFS) and overall survival (OS) curves were summarized by Kaplan-Meier method and compared using the log-rank test.

Results: Of the 204 patients, 48 (23.53%) were CD5-positive. The 5-year PFS and OS rates for CD5-positive marginal zone lymphoma were 64.80% and 84.10%, there was no significant difference between CD5-positive and CD5-negative (P > 0.05). Diffuse large B cell lymphoma (DLBCL) transformation was pathologically indicated in 6 patients, of which 5 (83.33%) patients were CD5-positive marginal zone lymphoma.

Conclusion: CD5 expression in marginal zone lymphoma is not relevant to the prognosis of the patients, but CD5-positive marginal zone lymphoma seems more likely to transformation to diffuse large B-cell lymphoma.

Keywords: CD5; DLBCL; MZL; Transformation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Lymphoma, B-Cell, Marginal Zone*
Lymphoma, Large B-Cell, Diffuse*
Prognosis
Progression-Free Survival
Retrospective Studies